Distinct drug-interaction profiles for statins

被引：8

作者：

Bottorf, MB ^{[1
]}

机构：

[1] Univ Cincinnati, Coll Pharm, Div Pharm Practice, Cincinnati, OH 45267 USA

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 1999年 / 56卷 / 10期

关键词：

D O I：

10.1093/ajhp/56.10.1019

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1019 / 1020

页数：2

共 11 条

[1]

BOBOERG M, 1996, DRUG METAB DISPOS, V25, P321

[2]

*BRIST MYERS SQUIB, 1998, PRAV PACK INS

[3] Drug interaction inconsistency in Drug Information Handbook [J].

Jolley, MR ;

Bess, DT .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (22) :2418-2419

[4] Effect of itraconazole on the pharmacokinetics of atorvastatin [J].

Kantola, T ;

Kivistö, KT ;

Neuvonen, PJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :58-65

[5] Atorvastatin: A hydroxymethylglutaryl-coenzyme A reductase inhibitor [J].

Malinowski, JM .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (21) :2253-2267

[6] Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin [J].

Mück, W ;

Ochmann, K ;

Rohde, G ;

Unger, S ;

Kuhlmann, J .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 53 (06) :469-473

[7] Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole [J].

Neuvonen, PJ ;

Kantola, T ;

Kivistö, KT .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (03) :332-341

[8]

NKECHI EA, 1998, CLIN PHARMACOL THER, V64, P369

[9] IN-VIVO INHIBITION PROFILE OF CYTOCHROME P450(TB) (CYP2C9) BY (+/-)-FLUVASTATIN [J].

TRANSON, C ;

LEEMANN, T ;

VOGT, N ;

DAYER, P .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (04) :412-417

[10] Potential interaction between warfarin and fluvastatin [J].

Trilli, LE ;

Kelley, CL ;

Aspinall, SL ;

Kroner, BA .

ANNALS OF PHARMACOTHERAPY, 1996, 30 (12) :1399-1402

← 1 2 →